Engineering Skin Bacteria to Be Live Biotherapeutics

Travis Whitfill, co-founder and chief operating officer of Azitra, discusses Netherton syndrome, the company’s platform technology for engineering live biotherapeutic products, and why it takes more than simply inserting a gene into a desired bacteria to produce these treatments.